Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia

American Journal of Psychiatry

Volumn 157, Issue 4, 2000, Pages 514-520

  Kapur, Shitij ^a   Zipursky, Robert ^b   Jones, Corey ^b   Remington, Gary ^b   Houle, Sylvain ^b  

^a Ctr Addict and Mental Clark Div   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LORAZEPAM;

ADULT; ARTICLE; CLINICAL ARTICLE; DOPAMINE RELEASE; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPROLACTINEMIA; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CARBON RADIOISOTOPES; CORPUS STRIATUM; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; RACLOPRIDE; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0034025771     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.157.4.514     Document Type: Article

References (48)

1. Palermo-Neto J: Dopaminergic systems: dopamine receptors. Psychiatr Clin North Am 1997; 20:705-721
2. Seeman P, Lee T, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261:717-719
3. Seeman P, Corbett R, Van Tol HHM: Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors - reply. Neuropsychopharmacology 1997; 16:127-135
4. Sanberg PR: Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 1980; 284:472-473
5. Casey DE: Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys. Psychopharmacology (Berl) 1992; 107:18-22
6. Moore KE, Lookingland KJ: Dopaminergic neuronal systems in the hypothalamus, in Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York, Raven Press, 1994, pp 245-256
7. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B: Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology (Berl) 1989; 99:463-472
8. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996; 153:948-950
9. Goyer PF, Berridge MS, Morris ED, Semple WE, Compton-Toth BA, Schulz SC, Wong DF, Miraldi F, Meltzer HY: PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics. J Nucl Med 1996; 37:1122-1127
10. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue C-Y, Cooper TB, Brodie JD: Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989; 146:905-908
11. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
12. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G: Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33: 227-235
13. Brucke T, Roth J, Podreka I, Strobl R, Wenger S, Asenbaum S: Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics (letter). Lancet 1992; 339:497
14. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW: Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychol Med 1993; 23: 791-797
15. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), Clinician Version. Washington, DC, American Psychiatric Press, 1996
16. Kapur S, Zipursky R, Roy P, Jones C, Remington G, Reed K, Houle S: The relationship between D-2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology (Berl) 1997; 131:148-152
17. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152:173-178
18. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
19. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
20. Chouinard G, Ross-Chouinard A, Annable L, Jones BD: Extrapyramidal Symptom Rating Scale (ESRS) (abstract). Can J Neurol Sci 1980; 7:233
21. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
22. Kapur S, Zipursky RB, Jones C, Remington GJ, Wilson AA, DaSilva J, Houle S: The D-2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology 1996; 15:562-566
23. Woods RP, Grafton ST, Holmes CJ, Cherry SR, Mazziotta JC: Automated image registration, I: general methods and intrasubject, intramodality validation. J Comput Assist Tomogr 1998; 22:139-152
24. Woods RP, Grafton ST, Watson JDG, Sicotte NL, Mazziotta JC: Automated image registration, II: intersubject validation of linear and nonlinear models. J Comput Assist Tomogr 1998; 22:153-165
25. Farde L, Hall H, Ehrin E, Sedvall G: Quantitative analysis of D2 dopamine receptor binding in the living brain by PET. Science 1986; 231:258-261
26. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordstrom AL, Hall H, Sedvall G: D2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 1990; 47: 213-219
27. Hietala J, Syvalahti E, Vuorio K, Nagren K, Lehikoinen P, Ruotsalainen U, Rakkolainen V, Lehtinen V, Wegelius U: Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 1994; 51:116-123
28. The Scottish First Episode Schizophrenia Study, II: treatment: pimozide versus flupenthixol: the Scottish Schizophrenia Research Group. Br J Psychiatry 1987; 150:334-338
29. Lieberman J, Jody D, Geisler S, Vital-Herne J, Alvir JM, Walsleben J, Woerner MG: Treatment outcome of first episode schizophrenia. Psychopharmacol Bull 1989; 25:92-96
30. Remington G, Kapur S, Zipursky RB: Pharmacotherapy of first-episode schizophrenia. Br J Psychiatry Suppl 1998; 172: 66-70
31. McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia: a controlled study of neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48:739-745
32. Ahang-Wong J, Zipursky RB, Beiser M, Bean G: Optimal haloperidol dosage for first-episode psychosis. Can J Psychiatry 1999; 44:164-167
33. Scherer J, Tatsch K, Schwarz J, Oertel WH, Konjarczyk M, Albus M: D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr Scand 1994; 90:266-268
34. Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Charney DS, van Dyck C, Hoffer PB, Innis RP: [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46:231-237
35. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF: Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993; 34:423-431
36. Schlegel S, Schlosser R, Hiemke C, Nickel O, Bockisch A, Hahn K: Prolactin plasma levels and D-2-dopamine receptor occupancy measured with IBZM-SPECT. Psychopharmacology (Berl) 1996; 124:285-287
37. Davis KL, Kahn RS, Ko G, Davidson M: Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148:1474-1486
38. Farde L, Suhara T, Nyberg S, Karlsson P, Nakashima Y, Hietala J, Halldin C: A PET study of [C-11]FLB 457 binding to extrastriatal D-2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berl) 1997; 133:396-404
39. Hietala J, Vilkman H, Syvälahti E, Nagren K: Extrastriatal and striatal dopamine receptor occupancy by haloperidol and clozapine measured with PET, in Abstracts of the XXIst CINP Congress. Glasgow, UK, Collegium Internationale Neuro-Psychopharmacologicum, 1998, SW0104
40. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, VanGompel P, Lesage AS, DeLoore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124:57-73
41. Wadenberg ML, Salmi P, Jimenez P, Svensson T, Ahlenius S: Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat. Eur Neuropsychopharmacol 1996; 6:305-310
42. Prinssen EP, Ellenbroek BA, Cools AR: Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol 1994; 262:167-170
43. Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153: 466-476
44. Gerlach J, Peacock L: New antipsychotics: the present status. Int Clin Psychopharmacol 1995; 10:39-48
45. Meltzer HY, Matsubara S, Lee JC: The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25:390-392
46. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152:1444-1449
47. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NPLG, Kerwin RW: Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 340:199-202
48. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286-293